Ranges from single to multi-centre, national to international, phase II to phase IV drug trials, as well as other randomised control trials and well designed studies.
MELD-ATG is a multi-centre, randomised, double-blind, placebocontrolled, multi-arm parallel cohort trial. The purpose of this clinical trial is to confirm the effect of 2.5mg/kg of antithymocyte globulin (ATG) on the preservation of stimulated C-…
